Targeting the NOD-Like Receptor Pyrin Domain Containing 3 Inflammasome to Improve Healing of Diabetic Wounds.

IF 5.8 3区 医学 Q1 DERMATOLOGY
Advances in wound care Pub Date : 2023-11-01 Epub Date: 2022-01-13 DOI:10.1089/wound.2021.0148
Jacqueline Cavalcante-Silva, Timothy J Koh
{"title":"Targeting the NOD-Like Receptor Pyrin Domain Containing 3 Inflammasome to Improve Healing of Diabetic Wounds.","authors":"Jacqueline Cavalcante-Silva, Timothy J Koh","doi":"10.1089/wound.2021.0148","DOIUrl":null,"url":null,"abstract":"<p><p><b>Significance:</b> Chronic skin wounds are a significant health problem around the world, often leading to amputation and even death. Although persistent inflammation is a hallmark of these poorly healing wounds, few available therapies have been designed to target inflammation. In this review, we summarize available evidence of the role of the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome in impaired wound healing and describe strategies to inhibit the inflammasome to improve wound healing. <b>Recent Advances:</b> The NLRP3 inflammasome plays an important physiological role in skin wound healing, during which transient inflammasome activity contributes to both epidermal and dermal healing. In contrast, sustained activity of the NLRP3 inflammasome leads to impaired epidermal and dermal healing associated with diabetes. Of importance, preclinical studies have demonstrated that inhibiting the NLRP3 inflammasome-induced resolution of inflammation, increased granulation tissue formation and collagen deposition, and accelerated reepithelialization and wound closure. <b>Critical Issues:</b> NLRP3 inflammasome inhibitors have appealing potential for translation into therapies for chronic wounds. Although preclinical studies have shown promising results, there is a need for human/clinical studies to evaluate dosing formulations, potential therapeutic effects, dose-response relationships, and possible side effects. <b>Future Directions:</b> Among strategies to inhibit the NLRP3 inflammasome, glyburide, metformin, peroxisome proliferator-activated receptor agonists, and the dipeptidyl peptidase 4 inhibitor saxagliptin appear to be closest to clinical translation, as these drugs are already Food and Drug Administration approved for other indications. Future clinical studies are needed to develop topical formulations of these drugs, and to assess the safety and efficacy of these inhibitors, to improve healing of chronic wounds.</p>","PeriodicalId":7413,"journal":{"name":"Advances in wound care","volume":"12 11","pages":"644-656"},"PeriodicalIF":5.8000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701516/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/wound.2021.0148","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: Chronic skin wounds are a significant health problem around the world, often leading to amputation and even death. Although persistent inflammation is a hallmark of these poorly healing wounds, few available therapies have been designed to target inflammation. In this review, we summarize available evidence of the role of the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome in impaired wound healing and describe strategies to inhibit the inflammasome to improve wound healing. Recent Advances: The NLRP3 inflammasome plays an important physiological role in skin wound healing, during which transient inflammasome activity contributes to both epidermal and dermal healing. In contrast, sustained activity of the NLRP3 inflammasome leads to impaired epidermal and dermal healing associated with diabetes. Of importance, preclinical studies have demonstrated that inhibiting the NLRP3 inflammasome-induced resolution of inflammation, increased granulation tissue formation and collagen deposition, and accelerated reepithelialization and wound closure. Critical Issues: NLRP3 inflammasome inhibitors have appealing potential for translation into therapies for chronic wounds. Although preclinical studies have shown promising results, there is a need for human/clinical studies to evaluate dosing formulations, potential therapeutic effects, dose-response relationships, and possible side effects. Future Directions: Among strategies to inhibit the NLRP3 inflammasome, glyburide, metformin, peroxisome proliferator-activated receptor agonists, and the dipeptidyl peptidase 4 inhibitor saxagliptin appear to be closest to clinical translation, as these drugs are already Food and Drug Administration approved for other indications. Future clinical studies are needed to develop topical formulations of these drugs, and to assess the safety and efficacy of these inhibitors, to improve healing of chronic wounds.

靶向含有3种炎症小体的NOD样受体吡啶结构域以改善糖尿病伤口的愈合。
意义:慢性皮肤损伤是世界各地的一个重大健康问题,经常导致截肢甚至死亡。尽管持续的炎症是这些愈合不良伤口的标志,但很少有针对炎症的可用疗法。在这篇综述中,我们总结了NOD样受体pyrin结构域3(NLRP3)炎症小体在受损伤口愈合中作用的现有证据,并描述了抑制炎症小体以改善伤口愈合的策略。最新进展:NLRP3炎症小体在皮肤伤口愈合中发挥着重要的生理作用,在此过程中,短暂的炎症小体活性有助于表皮和真皮愈合。相反,NLRP3炎症小体的持续活性会导致与糖尿病相关的表皮和真皮愈合受损。重要的是,临床前研究表明,抑制NLRP3炎症小体可诱导炎症消退,增加肉芽组织的形成和胶原沉积,并加速再上皮化和伤口闭合。关键问题:NLRP3炎症小体抑制剂具有转化为慢性伤口治疗的吸引力。尽管临床前研究显示出了有希望的结果,但仍需要进行人体/临床研究来评估给药配方、潜在的治疗效果、剂量-反应关系和可能的副作用。未来方向:在抑制NLRP3炎症小体的策略中,格列本脲、二甲双胍、过氧化物酶体增殖物激活受体激动剂和二肽基肽酶4抑制剂沙格列汀似乎最接近临床转化,因为这些药物已经被美国食品药品监督管理局批准用于其他适应症。未来的临床研究需要开发这些药物的局部配方,并评估这些抑制剂的安全性和有效性,以改善慢性伤口的愈合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in wound care
Advances in wound care Medicine-Emergency Medicine
CiteScore
12.10
自引率
4.10%
发文量
62
期刊介绍: Advances in Wound Care rapidly shares research from bench to bedside, with wound care applications for burns, major trauma, blast injuries, surgery, and diabetic ulcers. The Journal provides a critical, peer-reviewed forum for the field of tissue injury and repair, with an emphasis on acute and chronic wounds. Advances in Wound Care explores novel research approaches and practices to deliver the latest scientific discoveries and developments. Advances in Wound Care coverage includes: Skin bioengineering, Skin and tissue regeneration, Acute, chronic, and complex wounds, Dressings, Anti-scar strategies, Inflammation, Burns and healing, Biofilm, Oxygen and angiogenesis, Critical limb ischemia, Military wound care, New devices and technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信